|
Termin heute: MONROVIA, Calif., Nov. 20, 2018 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 10:30 a.m. ET in New York, NY. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at http://investors.xencor.com/events.cfm. A replay of the presentation will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the presentation. |
|
| aus der Diskussion: | Antikörper-Optimierung durch Xencor |
| Autor (Datum des Eintrages): | Gustl24 (27.11.18 09:53:29) |
| Beitrag: | 224 von 268 (ID:59305235) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |